Universitat de Lleida
    • English
    • català
    • español
  • English 
    • English
    • català
    • español
  • Login
Repositori Obert UdL
View Item 
  •   Home
  • Recerca
  • Medicina Experimental
  • Articles publicats (Medicina Experimental)
  • View Item
  •   Home
  • Recerca
  • Medicina Experimental
  • Articles publicats (Medicina Experimental)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy

Thumbnail
View/Open
015599.pdf (327.1Kb)
Sol·licita una còpia
Issue date
2010
Author
Fourcade, Stéphane
Ruiz, Montserrat
Guilera, Cristina
Hahnen, Eric
Brichta, Lars
Naudí i Farré, Alba
Portero Otín, Manuel
Dacremont, Georges
Cartier, Nathalie
Wanders, Ronald
Kemp, Stephan
Mandel, Jean Louis
Wirth, Brunhilde
Pamplona Gras, Reinald
Aubourg, Patrick
Pujol, Aurora
Suggested citation
Fourcade, Stéphane; Ruiz, Montserrat; Guilera, Cristina; Hahnen, Eric; Brichta, Lars; Naudí i Farré, Alba; ... Pujol, Aurora. (2010) . Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy. Human Molecular Genetics, 2010, vol. 19, núm. 10, p. 2005-2014. https://doi.org/10.1093/hmg/ddq082.
Impact


Web of Science logo    citations in Web of Science

Scopus logo    citations in Scopus

Google Scholar logo  Google Scholar
Share
Export to Mendeley
Metadata
Show full item record
Abstract
X-linked adrenoleukodystrophy (X-ALD) is a fatal, axonal demyelinating, neurometabolic disease. It results from the functional loss of a member of the peroxisomal ATP-binding cassette transporter subfamily D (ABCD1), which is involved in the metabolism of very long-chain fatty acids (VLCFA). Oxidative damage of proteins caused by excess of the hexacosanoic acid, the most prevalent VLCFA accumulating in X-ALD, is an early event in the neurodegenerative cascade. We demonstrate here that valproic acid (VPA), a widely used anti-epileptic drug with histone deacetylase inhibitor properties, induced the expression of the functionally overlapping ABCD2 peroxisomal transporter. VPA corrected the oxidative damage and decreased the levels of monounsaturated VLCFA (C26:1 n-9), but not saturated VLCFA. Overexpression of ABCD2 alone prevented oxidative lesions to proteins in a mouse model of X-ALD. A 6-month pilot trial of VPA in X-ALD patients resulted in reversion of the oxidative damage of proteins in peripheral blood mononuclear cells. Thus, we propose VPA as a promising novel therapeutic approach that warrants further clinical investigation in X-ALD.
URI
http://hdl.handle.net/10459.1/58675
DOI
https://doi.org/10.1093/hmg/ddq082
Is part of
Human Molecular Genetics, 2010, vol. 19, núm. 10, p. 2005-2014
European research projects
Collections
  • Articles publicats (IRBLleida) [1161]
  • Articles publicats (Medicina Experimental) [349]
  • Publicacions de projectes finançats per la Unió Europea [758]
  • Publicacions de projectes de recerca del Plan Nacional [2953]
  • Articles publicats (Grup de Recerca en Fisiopatologia Metabòlica) [60]

Contact Us | Send Feedback | Legal Notice
© 2023 BiD. Universitat de Lleida
Metadata subjected to 
 

 

Browse

All of the repositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

Statistics

View Usage Statistics

D'interès

Política institucional d'accés obertDiposita les teves publicacionsDiposita dades de recercaSuport a la recerca

Contact Us | Send Feedback | Legal Notice
© 2023 BiD. Universitat de Lleida
Metadata subjected to